Samantha L. Heal

Samantha L. Heal

Auto-generated profile, based on publicly available information

Samantha L. Heal

4468 Discovery and Translational Science Department Leeds Institute of Cardiovascular and Metabolic Medicine University of Leeds Leeds UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KKKatherine Jennifer Kearney
Katherine Jennifer Kearney
JBJuliet Butler
Juliet Butler
OPOlga M. Posada
Olga M. Posada
CWClare Wilson
Clare Wilson
SHSamantha Heal
Samantha Heal
HPHelen Philippou
Helen Philippou
Significance: Prekallikrein (PK) is a zymogen that is converted to kallikrein (PKa) by factor (F)XIIa. PK and FXII reciprocally activate each other; the resulting FXIIa initiates activation of the coagulation system via the cleavage of FXI to FXIa, which then activates FIX. This manuscript describes a novel high-affinity binding interaction between FIX(a) and PK(a) and reports that PKa can dose- and time-dependently activate FIX to generate FIXa, resulting in thrombin generation and clot formation independent of FXIa. Characterization of the kinetics of FIX activation reveal that PKa is a more significant activator of FIX than previously considered. This work highlights a new amendment to the coagulation cascade where PKa can directly activate FIX.

24 May 2022 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
SHSamantha L. Heal
Samantha L. Heal
LHLewis J. Hardy
Lewis J. Hardy
CWClare L. Wilson
Clare L. Wilson
MAMajid Ali
Majid Ali
RARobert A.S. Ariens
Robert A.S. Ariens
HPHelen Philippou
Helen Philippou
Evidence of crosstalk between the complement and coagulation cascades exists, and dysregulation of either pathway can lead to serious thromboinflammatory events. Both the intrinsic pathway of coagulation and the alternative pathway of complement interact with anionic surfaces, such as glycosaminoglycans. Hitherto, there is no evidence for a direct interaction of properdin (factor P [FP]), the only known positive regulator of complement, with coagulation factor XI (FXI) or activated FXI (FXIa). The aim was to investigate crosstalk between FP and the intrinsic pathway and the potential downstream consequences. Chromogenic assays were established to characterize autoactivation of FXI in the presence of dextran sulfate (DXS), enzyme kinetics of FXIa, and the downstream effects of FP on intrinsic pathway activity. Substrate specificity changes were investigated using SDS‐PAGE and liquid chromatography–mass spectrometry (LC‐MS). Surface plasmon resonance (SPR) was used to determine direct binding between FP and FXIa. We identified a novel interaction of FP with FXIa resulting in functional consequences. FP reduces activity of autoactivated FXIa toward S‐2288. FXIa can cleave FP in the presence of DXS, demonstrated using SDS‐PAGE, and confirmed by LC‐MS. FXIa can cleave factor IX (FIX) and FP in the presence of DXS, determined by SDS‐PAGE. DXS alone modulates FXIa activity, and this effect is further modulated by FP. We demonstrate that FXI and FXIa bind to FP with high affinity. Furthermore, FX activation downstream of FXIa cleavage of FIX is modulated by FP. These findings suggest a novel intercommunication between complement and coagulation pathways.